CEACAM5 and neoplasm: The patient was assessed as stable disease (SD) with an increase in tumor size based on the Response Evaluation Criteria on Solid Tumors (RECIST) version 1.1 after 4 cycles but with decreasing tumor serum marker carcinoembryonic antigen (CEA).